The FY2023 (Dec) proxy of Lexicon Pharmaceuticals names 14 peer companies for pay. Among Lexicon Pharmaceuticals and these peers, CEO pay was the lowest of 3 and total shareholder return was 2nd highest of 3.
3rd highest of 3in Lexicon Pharmaceuticals and its pay peers, FY2023 (Dec) by CEO pay:
$4.1M$32.3M
2nd highest of 3in Lexicon Pharmaceuticals and its pay peers, FY2023 (Dec) by total shareholder return:
$22$208
Pay peer group, FY2023 (Dec) proxy
| Madrigal Pharmaceuticals | ||
| Enanta Pharmaceuticals | ||
| 2seventy bio, Inc. | Not disclosed | Not disclosed |
| Amarin Corporation plc | Not disclosed | Not disclosed |
| Arcutis Biotherapeutics | Not disclosed | Not disclosed |
| Catalyst Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Chinook Therapeutics, Inc. | Not disclosed | Not disclosed |
| Esperion Therapeutics, Inc. | Not disclosed | Not disclosed |
| G1 Therapeutics, Inc. | Not disclosed | Not disclosed |
| Geron | Not disclosed | Not disclosed |
| Inovio Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Karyopharm Therapeutics, Inc. | Not disclosed | Not disclosed |
| Reata Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Y-mAbs Therapeutics, Inc. | Not disclosed | Not disclosed |
14 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.